COVID-19 vaccine developed by Valneva using Dynavax’s CpG 1018 adjuvant met co-primary endpoints in phase 3 trial
On Oct. 18, 2021, Dynavax Technologies announced that Valneva reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax’s CpG 1018ﾮ adjuvant.
Tags:
Source: Dynavax Technologies
Credit:
